JPMorgan lowered the firm’s price target on Regeneron (REGN) to $1,000 from $1,100 and keeps an Overweight rating on the shares. The firm ...

Opthea’s eye disease drug has failed its second phase 3 trial in a week, leaving the Australian biotech to discard the entire ...

Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD Following recent approvals in the EU, China, and the US, this approval was based on pivotal phase 3 results in adu ...

Annual Report/Annual ResultsFormycon reports on a successful financial year 2024 with strong operational progress and continuous strengthening of its market position 27.03.2025 / 06:30 CET/CESTThe ...

We recently compiled a list of the 12 Most Promising Biotech Stocks According to Wall Street Analysts. In this article, we are going to look at where Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) ...

UNITY Biotechnology stock loses 29% as the mid-stage DME study of the lead candidate, UBX1325, fails to achieve statistical ...

The Eylea franchise was in need of a win after an appellate court last week denied the pharma’s bid to block Amgen’s ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

The Australian biotech could potentially be on the hook for more than $1bn after sozinibercept failed to show impact over ...

Opthea's sozinibercept and Unity's UBX1325 fail to match Regeneron's Eylea in separate eye disease trials; Opthea faces ...

Unity Biotechnology’s investigational eye treatment failed to match Eylea at 20 weeks—part of the mid-stage trial’s primary ...

Opthea's Phase 3 COAST trial for wet AMD did not meet its primary endpoint, raising financial concerns as the company faces ...